Half of COVID-19 vaccine supply is booked by the rich nations


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ half-covid19-vaccine-supply-booked-rich-nations
Oxfam, a non-governmental organisation, analysed deals struck by pharmaceuticals and vaccine producers for the five leading vaccine candidates

A group of wealthy nations representing 13 percent of the global population has already bought up more than half of the promised doses of future Covid-19 vaccines, according to a report by Oxfam on Wednesday.

The non-governmental organization analyzed deals struck by pharmaceuticals and vaccine producers for the five leading vaccine candidates currently in late-stage trials, based on data collected by the analytics company Airfinity.

"Access to a life-saving vaccine shouldn't depend on where you live or how much money you have," said Robert Silverman of Oxfam America.

"The development and approval of a safe and effective vaccine are crucial but equally important is making sure the vaccines are available and affordable to everyone. Covid-19 anywhere is Covid-19 everywhere."

The five vaccines analyzed were from AstraZeneca, Gamaleya/Sputnik, Moderna, Pfizer, and Sinovac.

Oxfam calculated the combined production capacity of these five vaccine candidates at 5.9 billion doses, enough for three billion people given that all five future vaccines will or are highly likely to require two doses.

Supply deals have so far been agreed for 5.3 billion doses, of which 2.7 billion (51 percent) have been bought by developed countries, territories, and regions, including the US, UK, European Union, Australia, Hong Kong and Macau, Japan, Switzerland, and Israel.

The remaining 2.6 billion doses have been bought by or promised to developing countries including India, Bangladesh, China, Brazil, Indonesia, and Mexico, among others.

The non-profit added that one of the leading candidates, developed by Moderna, has received $2.5 billion in committed taxpayers' money, but has said it intends to make a profit and has sold the options for all its supply to rich nations.

Oxfam and other organizations are therefore calling for a "people's vaccine" free of charge, distributed fairly based on need.

"This will only be possible if pharmaceutical corporations allow vaccines to be produced as widely as possible by freely sharing their knowledge free of patents, instead of protecting their monopolies and selling to the highest bidder," Oxfam said.

It added that the estimated cost of providing a vaccine for everyone on Earth was less than one percent of the projected cost of Covid-19 to the global economy.

Tags : #WHO #Oxfam #COVID-19 #Vaccine #Rich #Nations

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026